Among the key inflammatory processes is the formation of multi-protein complexes called inflammasomes. The inflammasomes are part of the innate immune system and they play a vital role in recruiting immune cells to sites of infection and inflammation. Dysregulated inflammasome activation may promote inflammatory, metabolic and oncogenic processes that give rise to autoinflammatory, autoimmune, metabolic and chronic diseases. Among the inflammasomes, NLRP3 is the most studied and has gained attention from both academic researchers and pharmaceutical companies.
Aqilion has identified a novel pharmacological strategy for selectively modulating NLRP3 inflammasome signaling by modulating a key protein target. The Polaris project has the potential to be first in class with this novel mechanism of action, thus providing a clear differentiation in a highly competitive and relevant field.
Aqilion’s Polaris in-house project was launched in September 2020.